ad image

Company Info

WuXi Biologics

WuXi Biologics

CDMO

Overview

WuXi Biologics is a global leading biologics services provider that offers comprehensive, integrated, and highly customizable services. The company offers multinational pharmaceutical and biotechnological companies end-to-end solutions, empowering any company to discover, develop, and manufacture biologics from concept to commercial manufacturing. Their services are designed to help their worldwide clients shorten discovery and development time and lower the cost of biologics.
WuXi Biologics
Contributions
32 Contributions1 / 2
WuXi Biologics
Facility

WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland

WuXi Biologics

PR-M03-20-NI-019Mar 12, 2020
WuXi Biologics
Coronavirus

WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

WuXi Biologics

PR-M02-20-NI-033Feb 25, 2020
WuXi Biologics
Clinical Results

WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

WuXi Biologics

PR-M02-20-NI-032Feb 24, 2020
WuXi Biologics
Coronavirus

WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

WuXi Biologics

PR-M01-20-NI-041Jan 29, 2020
WuXi Biologics
M&A

Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

WuXi Biologics

PR-M01-20-NI-025Jan 16, 2020
WuXi Biologics

WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

WuXi Biologics

PA1806Jan 09, 2020
WuXi Biologics
Drug Development

WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers

WuXi Biologics

PR-M11-19-NI-018Nov 19, 2019
WuXi Biologics
Expansion

WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing

WuXi Biologics

PR-M06-19-NI-054Jun 27, 2019
WuXi Biologics
Vaccine

WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract

WuXi Biologics

PR-M05-19-NI-070May 24, 2019
WuXi Biologics
Strategic Partnership

I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

WuXi Biologics

PR-M04-19-NI-065Apr 19, 2019
WuXi Biologics
GMP

WuXi Biologics Receives EMA GMP Certificates

WuXi Biologics

PR-M03-19-NI-061Mar 22, 2019
WuXi Biologics
Finance

WuXi Biologics Continues to Deliver Record Results

WuXi Biologics

PR-M03-19-NI-052Mar 19, 2019
WuXi Biologics
Immuno-Oncology

ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million

WuXi Biologics

PR-M02-19-NI-067Feb 28, 2019
WuXi Biologics
Strategic Collaborations

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

WuXi Biologics

PR-M12-18-NI-053Dec 17, 2018
WuXi Biologics
Partnership

WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

WuXi Biologics

PR-M12-18-NI-003Dec 03, 2018
WuXi Biologics
Announcement

WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting

WuXi Biologics

PR-M11-18-NI-046-3401Nov 13, 2018
WuXi Biologics
Manufacturing

WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3

WuXi Biologics

PR-M07-18-NI-090Jul 26, 2018
WuXi Biologics
Strategic Partnership

WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership

WuXi Biologics

PR-M06-18-NI-004Jun 01, 2018
WuXi Biologics
Investment

WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore

WuXi Biologics

PR-M05-18-NI-111May 30, 2018
WuXi Biologics
Strategic Collaboration

WuXi Biologics and Bioasis Announce Initial Strategic Collaboration

WuXi Biologics

PR-M05-18-NI-087May 23, 2018
1 / 2